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Introduction
In the second half of the 20th century, the prenatal
diagnosis armamentarium changed dramatically with
the introduction of amniocentesis and chorionic villus
sampling. Both modalities are, however, invasive
techniques and carry a certain risk, albeit low (0.5–1%),
of pregnancy loss [1]. Routine noninvasive methods of
prenatal diagnosis include first- and second-trimester
ultrasonography and maternal serum biochemical
screening. When screening women less than 35 years of
age, second-trimester measurements of _-fetoprotein,
human chorionic gonadotropin (hCG), and estriol
correctly identify only 60–70% of cases of aneuploidy,
with a calculated false-positive rate up to 5% [2]. Prenatal
ultrasound examination in the second and third tri-
mesters allows detection of only 17% of fetal anatomic
abnormalities [3]. In fact, in the USA, approximately 1
in 1,000 live-born fetuses are postnatally diagnosed with
Down syndrome. Most (80%) of these infants are born
to women under the age of 35 who have no indications
for routine invasive prenatal diagnostic procedures [4].
First-trimester ultrasonographic evaluation of fetal
nuchal translucency improves the aneuploidy detection
rate up to 82% but requires special sonographic expertise
[5]. Recent studies demonstrate that addition of first-
trimester biochemical markers (free `-hCG and
pregnancy-associated plasma protein-A) can increase
sensitivity and improve false-positive rates [6]. Other
first-trimester sonographic markers, including the
absence of nasal bone and abnormal ductus venosus
flow, have potential to improve the positive predictive
value of screening, but require further validation [7,8].
Neither of these new techniques are devoid of false-
positive results and both are associated with high health
care costs of invasive follow-up studies and patient
emotional anxiety [4].
The recovery of fetal genetic material in the form of
fetal cells or cell-free fetal DNA from maternal circulation
has, therefore, tremendous potential for prenatal
diagnosis. Analysis of fetal genetic material acquired by
means of routine venipuncture can potentially replace
current standard biochemical screening or become an
additional noninvasive technique to reduce the false-
positive rates of biochemical and ultrasonographic
screening programs.
Fetal Cells in Maternal Circulation
Fetal trophoblasts in maternal blood were first observed
by the German pathologist Schmorl in 1893 during
postmortem examination of the lung tissue of women
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dying from eclampsia [9]. These findings were
subsequently confirmed by other authors, but the
question remained of whether fetal cells are routinely
present in the maternal blood of healthy women. In
1957, Kleihauer et al identified fetal cells in the periph-
eral blood of pregnant women using a stain for fetal
hemoglobin [10]. Douglas et al, in 1959, sampled large
uterine veins during cesarean sections in 13 non-pre-
eclamptic patients and demonstrated that large mul-
tinucleated cells of fetal origin were present in eight
women [11]. Clayton et al demonstrated progressive
increase in the detection rate of fetal cells in maternal
circulation as a function of gestational age [12]. Fetal
cells were observed in 5% of pregnancies by 16 weeks of
gestation, but this reached almost 50% by 40 weeks. In
1969, Walknowska et al performed karyotypical analysis
of cultured lymphocytes derived from peripheral blood
of pregnant women. In 19 of 22 women carrying male
fetuses, 46XY cells were identified [13]. These results
were effectively reproduced and, by the early 1970s, the
concept of fetal cell transfer into maternal circulation
had become widely accepted. The labor-intensive and
low-yield cytogenetic methods used in the quoted studies
were subsequently replaced by newly developed cell-
sorting techniques.
Various fetal cells recovered from maternal circulation
were evaluated to determine the ideal cell type for
prenatal diagnosis. Trophoblasts, being uniquely fetal
in origin and in constant close contact with the uterine
stroma, initially appeared to be a realistic choice. Indeed,
deportation of trophoblasts to maternal circulation
occurs relatively early in the first trimester, and would be
ideal for early prenatal diagnosis. More than 6,500
monoclonal antibodies specific for trophoblast antigens
were developed to differentiate trophoblastic cells from
maternal cells, but only a handful could be used for
successful separation. Mueller et al used polymerase
chain reaction (PCR) amplification of a Y-chromosome-
specific sequence in isolated trophoblasts to correctly
predict fetal gender in 12 of 13 evaluated pregnancies
[14]. Significant cross-reactivity between apparently
trophoblast-specific monoclonal antibodies and other
cell types have been reported by Bruch et al, where
“pure” monoclonal antibodies GB17, GB21, and GB25
failed to identify trophoblastic cells in maternal cir-
culation [15]. Apart from the relative paucity of mono-
clonal antibodies, other factors make trophoblast cells
unlikely candidates for prenatal diagnosis. On enter-
ing maternal blood, trophoblasts are rapidly cleared
by the maternal pulmonary microcirculation and are,
therefore, rarely found in peripheral blood. The 1%
prevalence of confined placental mosaicism makes
trophoblast sprouts an unreliable representation of
the exact chromosomal complement of the fetus.
Additionally, the multinucleated nature of trophoblast
sprouts renders them unsuitable for analysis using
fluorescent in situ hybridization (FISH), which requires
visualization of individual nuclei.
Paternally inherited human leukocyte antigen (HLA)
allows initial separation of fetal lymphocytes from
maternal blood via flow cytometry [16]. This approach,
however, requires paternal HLA typing and is not
possible when parental HLA antigens are identical.
To complicate matters further, fetal production of
lymphocytes is not initiated until the second trimester,
further delaying prenatal diagnosis based on fetal
lymphocyte identification. Persistence of fetal lympho-
cytes in maternal circulation has been described to be
as long as 27 years following the index pregnancy, and
these findings can be misleading when isolation of
fetal lymphocytes is performed in multigravid women,
because separated cells might not necessarily represent
the current pregnancy [17].
Among other fetal cells isolated in maternal
circulation, fetal platelets and granulocytes hold little
promise for successful prenatal diagnosis. Fetal platelets
are devoid of nuclear genetic material and are generally
not useful for karyotyping and amplification of nuclear
genomic sequences [18]. The limited number of fetal
granulocytes detected in maternal blood specimens
impedes their use as target cells for noninvasive pre-
natal diagnosis. It is estimated that fetal granulocytes
constitute only 0.02–0.16% of the mononuclear cells
present in peripheral blood, and the role of these cells
in prenatal diagnosis remains largely unexplored [19].
Fetal nucleated red blood cells currently appear to
be the most realistic candidate for noninvasive prenatal
diagnosis. Firstly, nucleated red blood cells are relatively
rare in adult maternal circulation, except under
conditions of expansion of erythroid precursors, but are
quite abundant in the fetus, particularly during first-
trimester yolk sac hematopoiesis. Secondly, the nucleus
of the fetal red blood cell contains the full complement
of genetic material, which can be subjected to standard
genetic analysis once the cells are isolated. Thirdly,
nucleated red blood cells represent a relatively well-
differentiated cell type and are characterized by a short
life span, making it unlikely that they will persist in
maternal circulation from one pregnancy to another.
Nucleated fetal red blood cells possess several unique
cell-surface markers that can be used for automated
cell-sorting and enrichment. These markers include,
among others, a specific transferrin receptor antigen
(CD71), which is expressed only at the erythroblast
stage of development of red blood cells, and glycophorin
A, which is uniquely expressed by the erythroid cell line.
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Together, these cell-surface antigens, when applied to
isolation of fetal nucleated red blood cells, allow 94%
accuracy in prediction of fetal gender, as reported by
Wachtel et al [20]. The search for a truly specific
monoclonal antibody unique to fetal red blood cell
antigens is still unfinished.
Fetomaternal transfer of nucleated red blood cells
has been reported to occur as early as 6 weeks of
gestation [4]. The estimated ratio of fetal nucleated
red blood cells to maternal cells has been quoted at
1:100,000 in the first trimester and 1:10,000 at term
[21]. Enrichment of fetal nucleated erythrocytes from
maternal peripheral blood relies on the difference in cell
size, volume, and DNA content. Based on these
parameters, fetal cells can initially be separated by
density gradient centrifugation or lysis of maternal
anuclear erythrocytes. The remaining cell population
can be further purified using magnetic-activated cell
sorting (MACS), fluorescence-activated cell sorting
(FACS), antibody-conjugated columns, or immuno-
magnetic beads. A recent prospective, multicenter
clinical project demonstrated the superiority of MACS
over FACS in target-cell recovery and fetal-cell de-
tection [22].
Genetic analysis of isolated nucleated fetal red blood
cells is hindered by their resistance to mitogen action
and is, therefore, limited to FISH or PCR methodologies.
These techniques do not require the presence of a
dividing cell, but neither of them is capable of providing
complete karyotypic characteristics. PCR allows
detection of known fetal gene sequences, but will
generally not help if both parents are carriers of the
same autosomal recessive mutation or if the disease is
X-linked. FISH allows detection of chromosomal nu-
merical abnormalities and fetal gender. Other inherent
limitations of FISH stem from its inability to detect most
structural chromosomal rearrangements, its lack of
sensitivity to mosaicism, and unknown rates of cross-
hybridization and standard background hybridization.
In 1990, Camaschella et al were the first to achieve
successful prenatal diagnosis of an inherited disease
using fetal cells recovered from maternal blood [23].
Fetal hemoglobin Lepore-Boston disease was diagnosed
using PCR analysis of fetal nucleated red blood cells
isolated from maternal blood. PCR primers were used
to amplify a known mutation sequence of a hybrid
delta-beta gene mapped to chromosome 11. Two
affected pregnancies were detected and both were
confirmed by chorionic villus sampling. Other unique
fetal sequences were subsequently detected by PCR and
included Y-chromosome genes, mutations associated
with ` -thalassemia and sickle-cell anemia, survival motor
neuron gene mutations associated with spinal muscular
atrophy, mutations associated with Duchenne muscular
dystrophy, and HLA DR and DQ alpha genes [4,18,24].
In 1994, Lo et al reported successful use of PCR with
nucleated fetal red blood cells enriched from maternal
blood for detection of fetal Rhesus (Rh) genotype in
three cases of RhD sensitized pregnancies [25]. Fetal
nucleated red blood cells were recovered from second-
trimester specimens of maternal blood and PCR
amplification using RhD gene primers allowed correct
prediction of the fetal rhesus status that was confirmed
via cordocentesis. Geifman-Holtzman et al, using the
same principle, demonstrated a 100% positive predictive
value and 67% negative predictive value in fetal Rh
typing in maternally-derived fetal nucleated red blood
cells [26]. Similar results were reported by Sekizawa et
al [27].
In 1991, Price at al were the first to report successful
prenatal diagnosis of fetal numerical chromosomal
abnormality using FISH cytogenetic analysis of
maternally derived fetal cells [28]. Fetal cells enriched
from maternal blood at 10 weeks’ gestation
demonstrated three fluorescent signals on FISH with a
chromosome-18 probe. Suspected fetal trisomy 18 was
confirmed by chorionic villus sampling and tissue karyo-
typing upon termination of pregnancy. The follow-
ing year, Elias et al reported the first case of pre-
natally diagnosed trisomy 21 using FISH in maternally
derived fetal cells [29]. The reproducibility of these
results was confirmed and, from 1998, almost all
numerical abnormalities of fetal autosomes and sex
chromosomes have been detected in maternal blood by
FISH [4].
The practicality of prenatal diagnosis with PCR and
FISH in maternally derived fetal cells was recently assessed
in a prospective, multicenter Fetal Cell Isolation Study
conducted by the National Institute of Child Health and
Human Development. The study involved nine different
academic centers (8 in the USA and 1 in Switzerland),
and represents the largest and most rigorous study
performed in the field. The goal was to determine the
cytogenetic accuracy of fetal gender and fetal aneuploidy
detection in fetal cells derived from maternal blood,
compared with amniocentesis and chorionic villus
sampling. The results from the first 5 years of the study
were recently reported [22]. A total of 2,948 blood
samples were processed and demonstrated that the
aneuploidy detection rate using fetal cell analysis from
maternal blood (74.4%; 95% confidence interval,
76.0%, 99.0%) was comparable to that of single-marker
prenatal serum screening. The second part of the study
is incorporating adjustments to ensure uniformity in
shipping, processing, and scoring protocols across
centers.
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Cell-free Fetal DNA in Maternal Circulation
A relatively new concept in the field of prenatal diagnosis
based on fetal genetic material detected in the maternal
circulation is analysis of cell-free fetal DNA present in
maternal blood. In 1977, Leon et al demonstrated that
large quantities of cell-free DNA are present in the
serum of patients with neoplasms, while minute amounts
of cell-free DNA can be recovered from serum of healthy
individuals (mean, 13 ( 3 ng/mL) [30].
Following the same train of thought, Lo et al, in
1997, were the first to use PCR with SRY gene primers on
plasma from women pregnant with male fetuses. These
experiments recovered significant quantities of male
fetal DNA sequences in maternal plasma and serum
[31]. The same group later demonstrated that the
concentration of cell-free fetal DNA is significantly higher
in maternal plasma than serum and increases in both
compartments as a function of gestational age [32].
Mean concentration of cell-free fetal DNA measured
during the first and early second trimester in serum
versus plasma was 0.13% versus 3.4 %, and increased
later in pregnancy to 1% versus 6.2%.
The precise cellular origin of cell-free fetal DNA in
maternal blood is currently unknown. The universality
of the previously discussed fetomaternal cellular
transport during pregnancy suggests that constantly
transmigrating fetal cells and placental trophoblastic
cells are continuously destroyed by the maternal immune
system, liberating fetal DNA into the circulation.
Alternatively, naturally occurring apoptosis of fetal cells
entering maternal blood may be responsible for the
release of fetal DNA [33]. The progressive increase in
fetal DNA concentration in maternal plasma and serum
may be facilitated by the developmental apoptotic
process in placental tissue that has been reported to
increase as pregnancy advances [34]. Active remodeling
of trophoblasts results in deportation of liberated DNA
into the maternal circulation, and may enhance the
permeability of the fetomaternal interface, leading to
higher numbers of fetal cells entering the maternal
circulation. This notion is further supported by the
increased fetomaternal transfusion in conditions
associated with structural and functional pathology of
the uteroplacental unit: pre-eclampsia, intrauterine
growth restriction, and aneuploidy [35,36].
Circulating cell-free fetal DNA is short-lived compared
with intact fetal cells in maternal blood. Lo et al studied
postpartum clearance of fetal DNA and demonstrated
that, in most cases, the levels were undetectable by
conventional methods as early as 2 hours postpartum
[37]. Such a short half-life associated with consistent
detection of cell-free DNA throughout gestation makes
this approach particularly attractive for noninvasive
prenatal diagnosis, as identified fetal DNA sequences
appear to be unique to the current pregnancy and are
extremely unlikely to represent prior gestations. Complex
enrichment procedures used in detection of fetal cells in
maternal plasma are not necessary for recovery of cell-
free fetal DNA. Cell-free fetal DNA is more abundant
than DNA extracted from nucleated red blood cells in
the same volume of blood, and is readily analyzed by
PCR assay [31].
In 1998, Lo et al described a real-time quantitative
PCR assay for analysis of cell-free fetal DNA in maternal
blood [32]. Leung et al, evaluating 20 women with ges-
tational age between 26 and 34 weeks, demonstrated
significantly higher concentrations of cell-free fetal DNA
in women with spontaneous preterm delivery compared
with those in women without preterm labor compli-
cations [38]. Interestingly, successful tocolysis was
associated with lower concentrations of cell-free fetal
DNA, and the authors propose this approach as a
potential diagnostic test to identify patients in true
preterm labor.
In a study comparing 20 third-trimester women with
pre-eclampsia with 20 healthy controls, Lo et al noted
a fivefold increase in the median concentration of cell-
free fetal DNA in the former group (381 vs 76 genome-
equivalents/mL; p < 0.001) [39]. These findings further
support the hypothesis that the apoptotic process in
the pre-eclamptic placenta contributes to the presence
of cell-free fetal DNA in maternal blood, either
independently or by facilitation of fetal cell transfer to
maternal circulation.
Abnormally high concentrations of fetal genomic
DNA measured in fetal cells recovered from maternal
blood in women with a trisomy 21 fetus prompted
assessment of cell-free fetal DNA concentrations in
maternal blood in pregnancies with fetal aneuploidy
compared with chromosomally normal fetuses [40,
41]. In 1999, Lo et al reported significantly higher con-
centrations of cell-free fetal DNA in pregnancies com-
plicated by fetuses with trisomy 21 [41]. Results reached
statistical significance (p = 0.026), but considerable
overlap between values reported in the groups carrying
chromosomally normal fetuses and fetuses with trisomy
lowered the positive and negative predictive values of
the test. Recently, Wataganara et al described the first
noninvasive method for prenatal diagnosis of trisomy
13 [42]. Comparing cell-free fetal DNA concentrations
in serum samples from pregnancies with confirmed
trisomy 13 and 18 with those from pregnancies with
the normal fetal chromosomal complement, they dem-
onstrated significantly higher concentrations in the
trisomy 13 but not trisomy 18 group (p = 0.016). These
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findings create the possibility of a noninvasive prenatal
screening tool for detection of fetal trisomy 13, which
currently cannot be inferred from accepted biochemical
screening.
Qualitative assessment of cell-free fetal DNA in
maternal blood allows detection of paternally inherited
microsatellite polymorphisms and mutations associ-
ated with single-gene disorders [43]. Fetal gender
determination by demonstration of SRY gene sequences
in maternal blood seemed the most natural application
of the concept. Costa et al analyzed 121 first-trimester
pregnant women carrying 61 karyotypically confirmed
male and 60 karyotypically confirmed female fetuses.
Cell-free fetal DNA was extracted from maternal blood
and SRY PCR analysis demonstrated complete con-
cordance with fetal sex: 100% sensitivity and 100%
specificity [44]. Thus, reliable, noninvasive first-trimester
fetal sex determination has been achieved.
High concentrations of cell-free fetal DNA in mater-
nal plasma allowed a remarkable breakthrough in
noninvasive determination of fetal RhD genotype. In
1998, Lo et al reported results of real-time PCR detection
of RhD sequences in the plasma of 57 RhD-negative
pregnant women [45]. In the samples obtained during
the first trimester, there were two false-negative results,
but results of RhD PCR analysis of maternal plasma
fetal cell-free DNA obtained during the second and
third trimesters demonstrated complete concordance
with results obtained from serologic testing of cord
blood or genotyping of amniotic fluid. Follow-up studies
confirmed the findings of Lo et al, demonstrating the
high reliability of the method, particularly during the
second and third trimesters [46,47]. Reliable results are
achieved even when different regions of the RhD gene
are used in PCR amplification.
Analysis of paternally inherited microsatellite
polymorphisms in cell-free fetal DNA sequences
recovered from maternal blood has been described for
chromosomes 13, 18, and 21, as well as the paternally
inherited X-chromosome [48,49]. Clinical applicability
of maternal plasma DNA analysis has been further
supported by successful prenatal diagnosis of a number
of single-gene disorders. Amicucci et al described
prenatal diagnosis of myotonic dystrophy by detection
of paternally derived expanded alleles of the dystrophia
myotonica protein kinase gene in fetal DNA recovered
from maternal plasma samples [50]. Saito et al reported
noninvasive prenatal diagnosis of achondroplasia by
demonstrating a diagnostic G-to-A transition at position
1138 of the fibroblast growth factor receptor gene in a
DNA sample extracted from maternal plasma [51].
Additional examples of paternal polymorphisms and
mutations that might be detected through analysis of
cell-free fetal DNA extracted from maternal plasma
include, among others, such autosomal recessive
disorders as cystic fibrosis and hemoglobinopathies,
when father and mother are carriers of discordant
mutations [52]. A unique application of the meth-
odology for antenatal diagnosis of fragile X syn-
drome was recently reported by Wald and Morris [53].
SRY PCR of fetal cell-free DNA was used to detect fetal
gender, with subsequent invasive testing of male
fetuses known to be at higher risk of the serious form
of this disease. This approach opens clinical frontiers
for application of noninvasive prenatal diagnosis for
a wide spectrum of sex-linked diseases.
Conclusion
The present status of prenatal diagnosis using fetal
genetic material in maternal circulation is in transition
from the laboratory to active clinical practice.
It has become generally accepted that FISH and
PCR analysis of fetal cells recovered from maternal
circulation allow detection of gender and aneuploidy
as well as identification of paternally inherited unique
gene sequences. In specific instances, when parents
are carriers of different mutations responsible for
autosomal-recessive diseases, prenatal characteriza-
tion of fetal status with respect to the paternally de-
rived mutation is also possible. Sensitivity of fetal
aneuploidy detection, as confirmed by a recent multi-
center study, is at least comparable to that of second-
trimester serum marker screening. This approach is,
however, limited by maternal genetic material con-
tamination and low fetal cell numbers recovered from
maternal blood by current cell separation techniques.
Quantitative and qualitative assessment of cell-free
fetal DNA in maternal plasma and serum can be
important in the selection of pregnancies at risk of fetal
aneuploidy and complications such as pre-eclampsia
and preterm labor. Similar to PCR analysis of fetal cells,
this approach allows prenatal detection of fetal gender
and paternally inherited single-gene diseases. The large
amounts and short half-life of cell-free fetal DNA present
in maternal plasma and the rapidity and reproducibility
of assays make this method highly attractive for future
clinical application in analysis of known gene sequences,
but not for karyotypic studies requiring FISH.
The full potential of prenatal diagnosis based on
genetic material recovered from maternal circulation
remains to be evaluated and utilized. The future
perfection of fetal-cell enrichment techniques and
methods for recovery of cell-free fetal DNA will broaden
the clinical availability and application of these ap-
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proaches. Quantitative assessment of cell-free fetal
DNA and FISH analysis of fetal cells can become com-
plementary to first- and second-trimester noninvasive
screening. The incidence of false-positive results in
first- and second-trimester biochemical and ultrasound
testing requiring invasive cytogenetic procedures can
be dramatically reduced by addition of noninvasive
screening based on fetal genetic material present in
maternal circulation. Alternatively, fetal genetic ma-
terial testing can be routinely incorporated as a standard
component of prenatal diagnosis algorithms.
Qualitative assessment of cell-free fetal DNA and
PCR analysis of fetal cells in maternal blood can en-
compass noninvasive prenatal diagnosis and screening
of common single-gene disorders, fetal RhD antigen
status, and detection of fetal gender. In fact, diagnostic
and clinically accepted testing of cell-free fetal DNA for
determination of fetal RhD antigen status is currently
offered in Spain and Basel, and is available on an ex-
perimental basis in several commercial laboratories
in the USA. Noninvasive determination of fetal RhD
status combined with ultrasonographic assessment
of mid-cerebral artery peak systolic velocity may, in
the near future, revolutionize the management of
pregnancies at risk for Rh isoimmunization. This
approach can obviate the need for amniocentesis to
investigate fetal anemia and fetal RhD antigen
genotyping.
Apart from prenatal diagnosis, evaluation of fetal
genetic material in maternal circulation can have
additional ramifications. Relatively recent identification
of fetal cell differentiation in the tissue of patients
suffering from autoimmune and immune-mediated
diseases may shed light on the putative pathogenesis of
these dysfunctions and on reparative tissue processes
[54,55]. Successful in vitro expansion of fetal cells
recovered from maternal blood can be implemented
in the field of therapeutic cloning and enhance existing
fetal cell-based noninvasive diagnostic protocols by
dramatically increasing the availability of these cells
[56]. However, the ability to clonally expand recovered
fetal cells in vitro has not yet been fully established [57].
Intriguing and controversial identification of fetal mRNA
sequences and intact fetal cells in maternal plasma
opens future research directions towards better
understanding of normal and pathologic functioning of
the fetomaternal unit [58–60].
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